Summary
InnoCAR-T is a Doctoral Network designed to provide training and carry out breakthrough research on the high impact field of Chimeric Antigen Receptor (CAR) T cell immunotherapy in a carefully integrated academic and inter-sectoral programme. We aim to develop next-generation CAR-T therapy and deliver a set of young researchers uniquely qualified for a career in academia and/or industry.
CAR-T cell therapy represents a revolutionary advance in oncology, particularly for B cell lymphoma patients. However, long-term response is still restricted to ~50% of patients, with resistance being even more prominent in other cancers. Thus, additional innovations to overcome resistance are needed to improve CAR-T responses. Unfortunately, the currently centralized production of CAR-T hampers rapid innovation and associates with prohibitive costs, long vein-to-vein time, and poor carbon footprint due to inter-continental delivery.
InnoCAR-T aims touse innovative academic and industrial concepts to address these issues by 1. developing innovative manufacturing solutions for CAR-T production at local academic hospitals and 2. developing the next-generation of more effective CAR-Ts.
At the core of InnoCAR-T is its training objective to offer a cutting-edge multidisciplinary training programme. Herewith, outstanding young scientists can generate breakthrough ideas and assume leading positions in academia and industry. The training programme includes an array of disciplines, ranging from biomedical sciences (e.g. immunology, CAR engineering, gene-editing), physical sciences to mechanical engineering.
Industrial partners are central to the programme and provide pivotal expertise on how to translate scientific discoveries into commercial reality. Inter-sectoral partners will host Doctoral Candidates, provide key secondments and network-wide training events. Further, InnoCAR-T will foster long-term multi-disciplinary research and bilateral co-operations between academia and industry.
CAR-T cell therapy represents a revolutionary advance in oncology, particularly for B cell lymphoma patients. However, long-term response is still restricted to ~50% of patients, with resistance being even more prominent in other cancers. Thus, additional innovations to overcome resistance are needed to improve CAR-T responses. Unfortunately, the currently centralized production of CAR-T hampers rapid innovation and associates with prohibitive costs, long vein-to-vein time, and poor carbon footprint due to inter-continental delivery.
InnoCAR-T aims touse innovative academic and industrial concepts to address these issues by 1. developing innovative manufacturing solutions for CAR-T production at local academic hospitals and 2. developing the next-generation of more effective CAR-Ts.
At the core of InnoCAR-T is its training objective to offer a cutting-edge multidisciplinary training programme. Herewith, outstanding young scientists can generate breakthrough ideas and assume leading positions in academia and industry. The training programme includes an array of disciplines, ranging from biomedical sciences (e.g. immunology, CAR engineering, gene-editing), physical sciences to mechanical engineering.
Industrial partners are central to the programme and provide pivotal expertise on how to translate scientific discoveries into commercial reality. Inter-sectoral partners will host Doctoral Candidates, provide key secondments and network-wide training events. Further, InnoCAR-T will foster long-term multi-disciplinary research and bilateral co-operations between academia and industry.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101072861 |
| Start date: | 01-01-2023 |
| End date: | 31-12-2026 |
| Total budget - Public funding: | - 2 618 856,00 Euro |
Cordis data
Original description
InnoCAR-T is a Doctoral Network designed to provide training and carry out breakthrough research on the high impact field of Chimeric Antigen Receptor (CAR) T cell immunotherapy in a carefully integrated academic and inter-sectoral programme. We aim to develop next-generation CAR-T therapy and deliver a set of young researchers uniquely qualified for a career in academia and/or industry.CAR-T cell therapy represents a revolutionary advance in oncology, particularly for B cell lymphoma patients. However, long-term response is still restricted to ~50% of patients, with resistance being even more prominent in other cancers. Thus, additional innovations to overcome resistance are needed to improve CAR-T responses. Unfortunately, the currently centralized production of CAR-T hampers rapid innovation and associates with prohibitive costs, long vein-to-vein time, and poor carbon footprint due to inter-continental delivery.
InnoCAR-T aims touse innovative academic and industrial concepts to address these issues by 1. developing innovative manufacturing solutions for CAR-T production at local academic hospitals and 2. developing the next-generation of more effective CAR-Ts.
At the core of InnoCAR-T is its training objective to offer a cutting-edge multidisciplinary training programme. Herewith, outstanding young scientists can generate breakthrough ideas and assume leading positions in academia and industry. The training programme includes an array of disciplines, ranging from biomedical sciences (e.g. immunology, CAR engineering, gene-editing), physical sciences to mechanical engineering.
Industrial partners are central to the programme and provide pivotal expertise on how to translate scientific discoveries into commercial reality. Inter-sectoral partners will host Doctoral Candidates, provide key secondments and network-wide training events. Further, InnoCAR-T will foster long-term multi-disciplinary research and bilateral co-operations between academia and industry.
Status
SIGNEDCall topic
HORIZON-MSCA-2021-DN-01-01Update Date
09-02-2023
Images
No images available.
Geographical location(s)
Search
Organisations
-
| ACADEMISCH ZIEKENHUIS GRONINGEN (Coördinator)
-
| EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH
-
| EUROPEAN HEMATOLOGY ASSOCIATION
-
| FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA
-
| Ghent University
-
| INTEGRA THERAPEUTICS S.L.
-
| Learning By Simulation
-
| SCINUS CELL EXPANSION NETHERLANDS B.V.
-
| UNIVERSIDAD POMPEU FABRA (UPF)
-
| UNIVERSITAT DE BARCELONA